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Abstract
Insomnia,	the	most	prevalent	sleep	disorder	worldwide,	confers	marked	risks	for	both	
physical and mental health. Furthermore, insomnia is associated with considerable 
direct	and	 indirect	healthcare	costs.	Recent	guidelines	 in	 the	US	and	Europe	une-
quivocally	conclude	that	cognitive	behavioural	therapy	for	 insomnia	(CBT-I)	should	
be the first-line treatment for the disorder. Current treatment approaches are in 
stark	contrast	to	these	clear	recommendations,	not	least	across	Europe,	where,	if	any	
treatment at all is delivered, hypnotic medication still is the dominant therapeutic mo-
dality.	To	address	this	situation,	a	Task	Force	of	the	European	Sleep	Research	Society	
and	 the	European	 Insomnia	Network	met	 in	May	2018.	The	Task	Force	proposed	
establishing	a	European	CBT-I	Academy	that	would	enable	a	Europe-wide	system	of	
standardized	CBT-I	training	and	training	centre	accreditation.	This	article	summarizes	
the	deliberations	of	the	Task	Force	concerning	definition	and	ingredients	of	CBT-I,	
preconditions	for	health	professionals	to	teach	CBT-I,	the	way	in	which	CBT-I	should	
be	taught,	who	should	be	taught	CBT-I	and	to	whom	CBT-I	should	be	administered.	
Furthermore,	diverse	aspects	of	CBT-I	care	and	delivery	were	discussed	and	incorpo-
rated into a stepped-care model for insomnia.
K E Y W O R D S
CBT-I,	cognitive	behavioural	therapy	for	insomnia,	European	CBT-I	Academy,	insomnia,	
stepped-care
1  | A SUMMARY OF PRESENT GUIDELINES
In the last 2 years, four national/international guidelines have been 
published concerning the diagnosis and treatment of insomnia. The 
focus of the present article will be on treatment.
The	American	College	of	Physicians,	 in	 a	 series	of	 three	 articles	
(Brasure	et	al.,	2016;	Qaseem,	Kansagara,	Forciea,	Cooke,	&	Denberg,	
2016;	Wilt	et	al.,	2016)	and	an	editorial	(Kathol	&	Arnedt,	2016),	came	
to	the	conclusion	that	cognitive	behavioural	therapy	for	insomnia	(CBT-
I)	 should	be	considered	 the	 first-line	 treatment	 for	all	 adult	patients	
presenting	with	 insomnia:	 “ACP	 recommends	 that	 all	 adult	 patients	
receive	cognitive	behavioral	therapy	for	insomnia	(CBT-I)	as	the	initial	
treatment	for	chronic	insomnia	disorder	(Grade:	strong	recommenda-
tion,	moderate	quality	evidence)”.	Furthermore,	for	adults	with	chronic	
insomnia,	 for	whom	CBT-I	was	either	unsuccessful	 or	unavailable,	 a	
shared decision approach, which includes a discussion of benefits and 
costs for the short-term use of medication, was suggested.
Wilt	et	al.	 (2016),	 from	 the	 same	series	of	 articles,	 focused	on	
pharmacological treatment and concluded that zopiclone, zolpidem 
and	 suvorexant	 may	 have	 a	 short-term	 positive	 effect	 on	 sleep	
outcomes in adults with insomnia, but the comparative effective-
ness	 and	 long-term	 efficacy	 of	 pharmacotherapies	 are	 unknown.	
Furthermore, undesirable side-effects of hypnotic medications were 
stressed.
The	 American	 Academy	 of	 Sleep	 Medicine	 (AASM;	 Sateia,	
Buysse,	Krystal,	Neubauer,	&	Heald,	2017)	 focused	exclusively	on	
the pharmacological treatment of insomnia and concluded that even 
for short-term pharmacological treatment the evidence for all inves-
tigated	substances	 (including	benzodiazepines,	Z-drugs,	melatonin-
ergic	agonists,	suvorexant	and	others)	is	at	best	“weak”.
For	Europe	in	general	and	Germany	specifically,	independently	
published	 guidelines	 (Riemann,	 Baglioni,	 et	 al.,	 2017;	 Riemann,	
Baum,	 et	 al.,	 2017)	 for	 the	 diagnosis	 and	 treatment	 of	 insomnia	
mirror	 the	 conclusions	 of	 the	 American	 College	 of	 Physicians.	
Based	on	a	thorough	analysis	of	all	meta-analyses	published	in	the	
field,	 these	 guidelines	 stated	 that	 CBT-I	 should	 be	 the	 first-line	
treatment for insomnia and that pharmacological treatment should 
only	be	considered	when	CBT-I	was	unsuccessful	or	not	available.	
In	the	UK,	the	British	Association	for	Psychopharmacology	(BAP)	
consensus	 statement	 has	 (since	 2010)	 recommended	 that	 “CBT-
based	 treatment	 packages	 for	 chronic	 insomnia,	 including	 sleep	
restriction and stimulus control, are effective; and should be of-
fered	to	patients	as	a	first-line	treatment”	(strength	of	evidence	A:	
directly	based	on	category	I	evidence)	(Wilson	et	al.,	2010,	2019).	
The	BAP	also	stated	 that	 increased	availability	of	 this	 therapy	 is	
required.
Comparing	 these	 statements	 to	 earlier	 published	 guidelines	 (for	
example	 Schutte-Rodin,	 Broch,	 Buysse,	 Dorsey,	 &	 Sateia,	 2008),	
the present guidelines reflect a complete shift in recommendations 
towards	CBT-I	as	 the	 first-line	 treatment,	and	away	 from	the	use	of	
sleeping	 pills.	 However,	 as	 Morin	 (2017)	 in	 his	 editorial	 about	 the	
European	guideline	(Riemann,	Baglioni,	et	al.,	2017)	noted,	the	central	
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challenge is the implementation of these clinical practice guidelines 
for the management of chronic insomnia within the various health-
care	systems	of	Europe.	Data	from	different	sources	indicate	that	at	
present,	CBT-I	 is	offered	only	to	a	very	small	proportion	of	patients	
suffering	 from	 chronic	 insomnia	 (e.g.,	 Koffel,	 Bramoweth,	 &	 Ulmer,	
2018).	Furthermore,	pharmacotherapy	is	still	by	far	the	most	prevalent	
intervention for insomnia in routine healthcare worldwide. Given the 
unequivocal	guideline	recommendation	of	CBT-I	as	the	first-line	treat-
ment for insomnia, and the fact that it is seldom available in practice, 
it	felt	timely	to	appoint	a	Task	Force	of	the	European	Sleep	Research	
Society	and	the	European	Insomnia	Network	with	the	aim	of	establish-
ing	a	European	CBT-I	Academy.	The	Academy's	aims	will	be	to	(a)	de-
fine	key	aspects	of	CBT-I	and	(b)	enable	a	Europe-wide	system	of	CBT-I	
training and training centre accreditation. This should in turn promote 
the	 availability	 of	 CBT-I,	 to	 similar	 standards	 and	 with	 comparable	
levels	 of	 dissemination,	 across	 Europe.	 This	 paper	 summarizes	 the	
deliberations	of	the	Task	Force,	including	an	overview	of	current	data	
on	 the	prevalence	of	 insomnia	 in	Europe	and	experts'	 estimation	of	
CBT-I	availability	in	the	12	European	countries	of	the	founding	mem-
bers	of	the	Academy	(Austria,	Estonia,	Finland,	France,	Germany,	Italy,	
Norway,	Poland,	Sweden,	Switzerland,	the	Netherlands	and	the	UK).
2  | AN INTRODUC TION TO INSOMNIA 
DISORDER IN EUROPE: EPIDEMIOLOGY 
AND COSTS
Table 1 provides an overview of epidemiological studies conducted 
in	 adult	 populations	 (age	≥	18	years)	 that	were	 identified	 through	
PubMed	and	PsycInfo	searches,	using	“insomnia”	AND	“prevalence”	
OR	“epidemiol*”	as	keywords	and	focusing	on	prevalence	of	insom-
nia	in	European	countries.
Epidemiological	 data	 for	 25	 European	 countries	were	 identi-
fied. These studies were grouped according to whether they con-
sidered	night-time	insomnia	symptoms	exclusively,	night-time	plus	
daytime insomnia symptoms, or more conservatively, insomnia 
diagnoses	as	defined	using	diagnostic	manuals	(e.g.,	International	
Classification	 of	 Diseases	 (ICD)-10,	 Diagnostic	 and	 Statistical	
Manual	 of	 Mental	 Disorders	 (DSM)-IV,	 DSM-5,	 International	
Classification	of	 Sleep	Disorders	 (ICSD)-2	or	 ICSD-3).	As	 can	be	
seen,	by	any	metric,	insomnia	is	very	common.	Although	estimates	
vary,	 the	 median	 European	 prevalence	 for	 insomnia	 with	 night-
time symptoms alone is 24.8%, 12.5% for night-time together with 
daytime symptoms and 10.1% for full insomnia diagnosis.1	When	
looking	at	the	percentage	of	insomnia	diagnoses	across	different	
countries,	Germany	with	5.7%	and	the	UK	with	5.8%	seem	to	have	
the	lowest	percentage,	whereas	Norway,	France	and	Russia,	with	
percentages,	respectively,	of	20%,	19%	and	23.1%,	show	the	high-
est values.
Recent	 data	 from	 Germany	 (Marschall,	 Nolting,	 Hildebrandt-
Heene,	&	 Sydow,	 2017),	 based	 on	 longitudinal	 epidemiological	 data	
from more than 5,000 representative participants, indicate an increase 
in	 the	prevalence	of	 insomnia	from	2009	to	2016,	and	a	marked	 in-
crease in hypnotic prescriptions. Comparing 2009–2016, the preva-
lence	of	adults	who	had	taken	hypnotic	medication	at	least	once	a	year	
increased	from	13.5%	to	17.3%.	The	intake	of	hypnotic	medication	in	
the	last	3	months	prior	to	investigation	increased	from	4.7%	to	9.2%	for	
the	whole	sample.	Data	from	this	detailed	report	indicate	that	38%	of	
adults suffering from insomnia received a recommendation for psycho-
therapy. However, it remains unclear what type of psychotherapy was 
recommended and whether it was actually received. Similar data have 
been	published	for	Norway	(Pallesen	et	al.,	2001;	Pallesen,	Sivertsen,	
Nordhus,	&	Bjorvatn,	2014).	 In	 a	Norwegian	 study,	80%	of	patients	
who used sleeping medications in the past reported a preference 
for	a	non-pharmacological	treatment	alternative	(Omvik	et	al.,	2010).	
However, less than 10% of these patients had actually been offered 
anything other than sleeping medications.
In	Austria	 there	was	 a	 report	of	 a	 slight	decrease	 in	diagno-
ses	 of	 some	 sleep	 disorders	 from	 1997	 to	 2007	 (Zeitlhofer	 et	
al.,	2010).	However,	there	are	no	data	on	how	many	patients	re-
ceive a recommendation for psychotherapy, how many actually 
receive	 psychotherapy	 and	what	 kinds	 of	 psychotherapy	 are	 ei-
ther recommended or provided. In this survey, only 7% of people 
suffering	 from	 sleep	 problems	 took	 medication	 and	 6%	 sought	
psychotherapy. Furthermore, a recent study provided evidence 
that	 in	 Austria,	 awareness	 of	 certain	 sleep	 disorders	 in	 women	
seems	 to	be	 lower	 than	 in	men	 (Auer,	Frauscher,	Hochleitner,	&	
Hoegl,	2018).
In an internet study conducted by The Dutch Brain Foundation, 
14%	of	people	with	sleep	complaints	were	reported	to	seek	help	from	
their	general	practitioner	(GP),	5%	sought	the	help	of	a	psychologist	
or	other	 therapist	and	about	4%	contacted	a	sleep	centre	 (van	der	
Velden	&	Wester,	2015).	In	line	with	these	data,	it	has	also	been	re-
ported that about 60% of the patients who received a preliminary 
sleep disorder diagnosis from their GP went on to receive a benzodiaz-
epine	prescription	(Hoebert,	Souverein,	Mantel-Teeuwisse,	Leufkens,	
&	Dijk,	2012).	These	data	suggest	that	only	a	small	proportion	of	peo-
ple	with	insomnia	receive	CBT-I	in	the	Netherlands.	Nevertheless,	in	
the	Netherlands	a	decrease	 in	 the	use	of	hypnotics	 and	 tranquiliz-
ers	has	also	been	documented	(Van	Laar,	2017).	A	similar	decreasing	
trend	emerged	 in	Finland	 (Kronholm,	Markkula,	&	Virta,	2012;	The	
Social	Insurance	Institution	of	Finland,	2016).	In	Sweden,	around	7%	
of adults use sleep medication, a figure that has slowly decreased in 
the	past	10	years	(The	Swedish	National	Board	of	Health	&	Welfare,	
2018).	A	survey	among	600	GPs	(response	rate,	58.7%)	showed	that	
95% prescribed sleeping medication to their insomnia patients, even 
though	 31%	 believed	 that	 sleeping	 medication	 was	 more	 harmful	
than the sleep problem itself. Moreover, 80% claimed that they often 
referred	insomnia	patients	for	CBT	and	24%	reported	sometimes	re-
ferring	patients	for	CBT.	However,	details	on	the	execution,	content	
and	 quality	 of	 these	 CBT	 interventions	 remain	 unknown	 (Swedish	
Agency	for	Health	Technology	Assessment	&	Assessment	of	Social	
Services,	2010).	In	France,	53%	of	patients	with	severe	insomnia	who	
were	surveyed	sought	help	for	their	 insomnia	 (Léger,	Guilleminault,	
1 For	those	studies	reporting	different	prevalence	values,	e.g.	for	women	and	for	men	
separately, the mean was calculated.
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TA B L E  1  Prevalence	of	insomnia	disorder	in	European	countries
Country Author (year) Sample size
% Insomnia symptoms
(the presence of night-
time symptoms)
% Insomnia 
syndrome
(the presence 
of night-time 
and daytime 
symptoms)
% Insomnia diagnosis
(insomnia diagnoses 
as outlined for 
example by ICD-10, 
DSM-IV, DSM-5, 
ICSD-2 or ICSD-3)
Austria Soldatos,	Allaert,	Ohta,	and	
Dikeos	(2005)#,*
490 19.0% 9.8%  
van	de	Straat	and	Bracke	
(2015)# 
54,722	(total	sample	
size)
20.5%   
Zeitlhofer	et	al.	(2010) 1,000	(women,	
n = 522; men, 
n	=	478)
18% 17%  
Belgium Soldatos	et	al.	(2005)#,* 6,832 36.0% 16.0%  
van	de	Straat	and	Bracke	
(2015)# 
54,722	(total	sample	
size)
27.0%   
Czech 
Republic
van	de	Straat	and	Bracke	
(2015)# 
54,722	(total	sample	
size)
25.0%   
Denmark van	de	Straat	and	Bracke	
(2015)# 
54,722	(total	sample	
size)
16.6%   
Estonia van	de	Straat	and	Bracke	
(2015)# 
54,722	(total	sample	
size)
30.5%   
Finland Ohayon	and	Partinen	(2002)* 982 37.6% 15.0% 11.7%
Hublin,	Partinen,	Koskenvuo,	
and	Kaprio	(2011)
12,126 12%	(daily	or	almost	daily)
40%	(weekly)
  
Kronholm	et	al.	(2016) 4,852–6,031	(differ-
ent samples over 
6	years)
9.0%–9.6%	(often)
40.3–45.3	(sometimes)
  
Lallukka	et	al.	(2016)#  1,885	(men)
1,875	(women)
8.1%	(frequent)
24.0%	(occasional)
9.2%	(frequent)
23,5%	(occasional)
  
France Léger,	Guilleminault,	Dreyfus,	
Delahaye, and Paillard 
(2000)*
12,778 29.0%  19.0%
Léger	et	al.	(2011) 1,004   12.0%
Chan-Chee	et	al.	(2011)    15.0%–20.0%
Beck,	Richard,	and	Leger	(2013) 27,653   15.8%
van	de	Straat	and	Bracke	
(2015)# 
54,722	(total	sample	
size)
28.0%   
Germany Schlack,	Hapke,	Maske,	Busch,	
and	Cohrs	(2013)
7,988   5.7%
Soldatos	et	al.	(2005)#,* 2,016 17.4% 5.2%  
van	de	Straat	and	Bracke	
(2015)# 
54,722	(total	sample	
size)
26.7%   
Schlarb,	Kulessa,	&	
Gulewitsch, 2012
2,196 16%  7.7%
Greece Paparrigopoulos	et	al.	(2010) 254 25.3%   
Hungary Novak,	Mucsi,	Shapiro,	
Rethelyi,	and	Kopp	(2004)
12,643 47.0%  9.2%
van	de	Straat	and	Bracke	
(2015)# 
54,722	(total	sample	
size)
28.1%   
Italy Ohayon	and	Smirne	(2002)* 3,970 27.6%  7.0%
van	de	Straat	and	Bracke	
(2015)# 
54,722	(total	sample	
size)
16.6%   
(Continues)
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Country Author (year) Sample size
% Insomnia symptoms
(the presence of night-
time symptoms)
% Insomnia 
syndrome
(the presence 
of night-time 
and daytime 
symptoms)
% Insomnia diagnosis
(insomnia diagnoses 
as outlined for 
example by ICD-10, 
DSM-IV, DSM-5, 
ICSD-2 or ICSD-3)
Lithuania Lallukka	et	al.	(2016)#,* 600	(men)
1,002	(women)
24.0%
30.0%
  
Netherlands Kerkhof	(2017) 2,089   8.2%	(men,	6.8%;	
women,	9.5%)
van	de	Straat	and	Bracke	
(2015)# 
54,722	(total	sample	
size)
16.8%   
Norway Bjorvatn,	Waage,	and	Pallesen	
(2018)
1,001   20.0%
Pallesen	et	al.	(2001),	Pallesen	
et	al.	(2014)
2,001
2,000
  11.7%
15.5%
Sivertsen	et	al.	(2009)* 47,000 13.5%   
Uhlig, Sand, Ødegård, and 
Hagen	(2014)
40,535   7.9%
Lallukka	et	al.	(2016)#,* 2,378(men)
3,858	(women)
4.0%
7.0%
  
Poland Nowicki	et	al.	(2016) 2,413 50.5%   
van	de	Straat	and	Bracke	
(2015)# 
54,722	(total	sample	
size)
31.2%   
Kiejna,	Wojtyniak,	
Rymaszewska,	and	
Stokwiszewski	(2003)
47,924	(non-insti-
tutionalized, adult 
respondents)
23.7%   
Portugal Ohayon	and	Paiva	(2005)* 1,858 28.1%  10.1%
Soldatos	et	al.	(2005)#,* 784 21.2% 6.2%  
van	de	Straat	and	Bracke	
(2015)# 
54,722	(total	sample	
size)
29.8%   
Romania Voinescu	and	Szentágotai	
(2013)
588 27.6%  15.8%
Russia Averina	et	al.	(2005)* 1,968	(men)
1,737	(women)
  11.3%
34.8%
Slovakia Soldatos	et	al.	(2005)#,* 502 32.0% 11.1%  
Slovenia van	de	Straat	and	Bracke	
(2015)# 
54,722	(total	sample	
size)
22.7%   
Spain Ohayon	and	Sagales	(2010) 4,065 20.8%  6.4%
Soldatos	et	al.	(2005)#,* 1,999 22.4% 8.2%  
van	de	Straat	and	Bracke	
(2015)# 
54,722	(total	sample	
size)
24.3%   
Sweden Mallon,	Broman,	Akerstedt,	
and	Hetta	(2014)
1,128 24.6%  10.5%
Ohayon	and	Bader	(2010) 1,209 32.1%	(women,	38.3%;	
men,	26.1%)
  
van	de	Straat	and	Bracke	
(2015)# 
54,722	(total	sample	
size)
19.0%   
Switzerland Stringhini	et	al.	(2015) 3,391 Women,	34.5%;	men,	
26.6%
  
van	de	Straat	and	Bracke	
(2015)# 
54,722	(total	sample	
size)
17.4%   
Turkey Benbir	et	al.,	(2015) 4,758 51.0%  12.2%
TA B L E  1   (Continued)
(Continues)
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Bader,	Lévy,	&	Paillard,	2002)	and	10.8%	of	adults	reported	regularly	
taking	medication	to	sleep	(Léger,	Poursain,	Neubauer,	&	Uchiyama,	
2008).	 In	 an	 observational	 epidemiological	 survey,	 it	was	 reported	
that, in Italy, insomnia symptoms are undertreated and GPs prefer 
the	 pharmacological	 approach,	 which	 is	 four	 times	 more	 frequent	
than	 any	 non-pharmacological	 therapy	 (78.6%	 vs.	 18.2%,	 Terzano,	
Cirignotta,	Mondini,	Ferini-Strambi,	&	Parrino,	2006).
Insomnia	is	a	costly	condition.	At	present,	it	has	been	shown,	on	
a	meta-analytic	level,	to	convey	increased	risks	of	cardiovascular	dis-
eases	(Li,	Zhang,	Hou,	&	Tang,	2014;	Sofi	et	al.,	2014;	Spiegelhalder,	
Scholtes,	 &	 Riemann,	 2010),	 obesity	 and	 development	 of	 diabetes	
(Anothaisintawee,	 Reutrakul,	 Van	 Cauter,	 &	 Thakkinstian,	 2016;	
Chan,	 Levsen,	 &	 McCrae,	 2018),	 depression	 (Baglioni	 et	 al.,	 2011;	
Hertenstein	et	al.,	2019),	anxiety	(Hertenstein	et	al.,	2019)	and	suicide	
(Norra	&	Richter,	2013;	Pigeon,	Pinquart,	&	Conner,	2012).	Wickwire	
(2019)	reported	that	untreated	insomnia	is	associated	with	increased	
all-causes healthcare utilization based on a randomly selected and 
nationally	 representative	 sample	 from	 the	USA.	Norwegian	 studies	
clearly	indicate	that	insomnia	significantly	predicts	sick	leave	and	dis-
ability	pension	(Overland	et	al.,	2008;	Sivertsen,	Krokstad,	Øverland,	
&	Mykletun,	2009).	In	fact,	insomnia	has	been	shown	to	be	a	stron-
ger	predictor	of	disability	pension	 than	depression	 (Overland	et	al.,	
2008).	In	a	Finnish	nationally	representative	study	it	was	concluded	
that	direct	costs	due	to	sickness	absence	could	decrease	by	up	to	20%	
if	sleep	disturbances	could	be	fully	addressed	(Lallukka	et	al.,	2014).
In	 Europe,	 data	 for	Germany	 (Thiart	 et	 al.,	 2016)	 have	 shown	
that direct and indirect costs for insomnia are around €40–50 billion 
annually. In France, direct costs were estimated at $2 billion USD in 
1995	(Léger,	Levy,	&	Paillard,	1999).	Indirect	costs	are	estimated	at	
€77 per employee per year for costs of absenteeism and €1,062 for 
productivity	 loss	 (Léger	&	Bayon,	2010;	Leger,	Massuel,	Metlaine,	
&	SYSYPHE	Study	Group,	2006).	Data	from	Sweden	indicate	lower	
direct and indirect costs of insomnia compared to Germany and 
France,	around	€325	million	annually	 (Swedish	Agency	for	Health	
Technology	Assessment	and	Assessment	of	Social	Services,	2010).	
This discrepancy between countries shows the heterogeneity of 
European	 health	 systems	 concerning	 insomnia	 care	 and	 probably	
a difference in calculation of indirect costs. Similar data are also 
available	for	the	USA	and	Canada.	Annual	direct	and	indirect	costs	
for insomnia have been estimated to be around $150 billion in the 
USA	 (Reynolds	 &	 Ebben,	 2017),	 being	 mainly	 related	 to	 indirect	
costs such as increased healthcare utilization, poorer performance 
at	work	and	enhanced	risk	of	accidents	(Wickwire,	Shaya,	&	Scharf,	
2016).	A	Canadian	study	(Daley,	Morin,	LeBlanc,	Grégoire,	&	Savard,	
2009)	reported	total	annual	costs	for	insomnia	disorder	alone	to	be	
around $6.5 billion and underlined that the highest costs were for 
alcohol	consumed	as	a	sleep	aid	(58%)	and	consultations	for	insom-
nia	(33%).	The	study	also	indicated	that,	similar	to	the	data	from	the	
USA,	 insomnia	 is	associated	with	significant	morbidity	 in	terms	of	
health	problems,	health	care	utilization,	work	absenteeism,	reduced	
productivity	and	risk	of	non-motor-vehicle	accidents.	Despite	indi-
vidual differences between countries, in all regions direct and indi-
rect costs are a heavy burden on society and general health budgets. 
Data	from	the	Sleep	Health	Foundation	in	Australia	in	2017	(Adams	
et	 al.,	 2017;	 Sleep	Health	 Foundation	 Report	 by	Deloitte	 Access	
Economics,	2017)	estimated	that	7.4	million	Australian	adults	expe-
rienced	poor	sleep,	resulting	in	both	insufficient	sleep	and	excessive	
daytime	 sleepiness.	This	was	associated	with	a	 cost	of	AUS$26.2	
billion	 in	 2016–2017:	AUS$1.8	 billion	 associated	with	 health	 sys-
tem	 costs,	 AUS$17.9	 billion	 associated	 with	 productivity	 losses,	
AUS$0.6	billion	with	informal	care	costs	and	AUS$5.9	billion	with	
other	financial	costs.	In	addition	to	these	costs,	a	further	AUS$40.1	
billion was associated with decreases in well-being. Improving ac-
cessibility to an effective, brief and relatively low-cost treatment 
such	as	CBT-I	is	thus	strongly	warranted.
3  | AN INTRODUC TION TO COGNITIVE 
BEHAVIOUR AL THER APY FOR INSOMNIA 
(CBT-I)
Cognitive	 behavioural	 therapy	 for	 insomnia	 (CBT-I)	 largely	 targets	
those factors that may maintain insomnia over time, such as dysregu-
lation of the sleep drive, sleep-interfering behaviours and cognitions, 
Country Author (year) Sample size
% Insomnia symptoms
(the presence of night-
time symptoms)
% Insomnia 
syndrome
(the presence 
of night-time 
and daytime 
symptoms)
% Insomnia diagnosis
(insomnia diagnoses 
as outlined for 
example by ICD-10, 
DSM-IV, DSM-5, 
ICSD-2 or ICSD-3)
United 
Kingdom
Calem	et	al.,	(2012) 5,425 38.6% 13.9% 5.8%
Ellis,	Perlis,	Neale,	Espie,	and	
Bastien	(2012)# 
1,095   7.9%
Morphy, Dunn, Lewis, 
Boardman,	and	Croft	(2007)*
2,363  37.0%  
ICD, International Classification of Diseases; DSM, Diagnostic and Statistical Manual of Mental Disorders; ICSD, International Classification of Sleep 
Disorders.
*Data from prior to 2010. 
#Multinational study that included other countries as well as the country of relevance. 
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attempts	 to	 control	 the	 sleep	 process	 and	 sleep-related	 anxiety.	 It	
typically consists of stimulus control therapy, sleep restriction therapy 
and a range of cognitive therapeutics, supplemented by psychoedu-
cation/sleep	hygiene	and	relaxation	training	(Riemann	&	Perlis,	2009).	
Table 2 summarizes the main interventional strategies included in a 
CBT-I	protocol.
The	efficacy	of	CBT-I	 for	ameliorating	night-time	symptoms	of	
insomnia alone or when it presents as comorbid with other mental 
and	somatic	disorders	has	been	shown	in	14	meta-analyses	(Geiger-
Brown	et	al.,	2015;	Ho	et	al.,	2015;	 Irwin,	Cole,	&	Nicassio,	2006;	
Johnson	et	al.,	2016;	Koffel,	Koffel,	&	Gehrman,	2015;	Miller	et	al.,	
2014;	Montgomery	 &	Dennis,	 2004;	Morin,	 Culbert,	 &	 Schwartz,	
1994;	 Murtagh	 &	 Greenwood,	 1995;	 Okajima,	 Komada,	 &	 Inoue,	
2011;	Pallesen,	Nordhus,	&	Kvale,	1998;	Tang	et	al.,	2015;	Trauer,	
Qian,	 Doyle,	 Rajaratnam,	 &	 Cunnington,	 2015;	 Wu,	 Appleman,	
Salazar,	&	Ong,	2015).	In	seven	meta-analyses	the	efficacy	of	CBT-I	
was	demonstrated	 for	daytime	or	comorbid	symptoms	 (Ballesio	et	
al.,	2018;	Belleville,	Cousineau,	Levrier,	&	St.	Pierre-Delorme,	2011;	
Ho	et	al.,	2015;	Johnson	et	al.,	2016;	Koffel	et	al.,	2015;	Tang	et	al.,	
2015;	Wu	et	al.,	2015).	CBT-I	 is	as	effective	as	sedative	hypnotics	
during	acute	treatment	(4–8	weeks;	Smith	et	al.,	2002)	and	is	more	
effective	 in	 the	 long	 term	 (Morin,	Colecchi,	 Stone,	 Sood,	&	Brink,	
1999).	CBT-I	is	associated	with	an	average	treatment	effect	of	about	
50% improvement, with large effect sizes that are reliably around 
1.0	 (Perlis,	 Jungquist,	 Smith,	 &	 Posner,	 2005).	 Follow-up	 studies	
showed	that	CBT-I	promotes	stable	changes	for	sleep	onset	latency	
and	wake	after	sleep	onset	and	slower	but	substantial	improvements	
for	total	sleep	time	(Perlis	et	al.,	2005).
Most	clinical	research	on	CBT-I	focuses	on	the	general	adult	pop-
ulation, including older adults. Traditionally, research has focused on 
recruited participants meeting criteria for insomnia but not necessarily 
representative	of	more	complex	or	typical	clinical	cases.	These	cases	
might	 include	young,	working	and	older	adults	with	insomnia	that	 is	
comorbid with different mental and somatic disorders, paediatric pop-
ulations presenting with developmental disabilities, pregnant women, 
women at postpartum, women going through the menopause, shift 
workers	 and	 those	 entering	 retirement.	 Recently,	 research	 has	 also	
focused	on	the	efficacy	and	clinical	effectiveness	of	CBT-I	 in	adults	
whose insomnia is comorbid with a wide range of mental and somatic 
disorders. Findings from such studies have afforded greater confi-
dence	in	the	applicability	of	CBT-I	to	insomnia	disorder,	wherever	and	
however	it	presents.	Likewise,	CBT-I	appears	to	be	applicable	to	pae-
diatric populations, including infants, toddlers, preschoolers, school-
age children, adolescents and young adults. Less evidence is available 
on	CBT-I's	applicability	to	some	specific	populations,	such	as	pregnant	
women, women going through the menopause, older adults with cog-
nitive impairment, children with developmental disabilities and shift 
workers.
4  | INSOMNIA: SCOPE OF THE PROBLEM 
AND CURRENT CLINIC AL PR AC TICE IN 
EUROPE
Although	insomnia	is	prevalent	and	costly,	there	is	a	lack	of	invest-
ment	in	evidence-based	first-line	treatment	(CBT-I).	This	may,	in	part,	
TA B L E  2  CBT-I	ingredients
CBT-I strategy Description
Sleep restriction Behavioural strategy:	A	method	which	aims	to	strengthen	homeostatic	sleep	pressure	and	stabilize	circadian	control	of	
sleep	and	wakefulness,	by	decreasing	the	opportunity	to	sleep	over	successive	nights.	Patients	are	instructed	to	restrict	
their	time	in	bed	to	match	their	average	(self-report	in	sleep	diaries)	total	sleep	duration.	The	time	in	bed	is	then	gradually	
increased	until	it	reaches	patients’	optimal	sleep	need.	An	alternative	method,	called	sleep compression, involves gradual 
constriction of time in bed, which is then similarly increased until reaching the optimal sleep need
Stimulus control Behavioural strategy:	A	set	of	instructions	that	aim	to	strengthen	the	bed	as	a	cue	for	sleep,	weakening	it	as	a	cue	for	activi-
ties	that	might	interfere	with	sleep,	and	helping	the	insomniac	acquire	a	consistent	sleep	rhythm,	based	on	operant	con-
ditioning	model:	(1)	Lie	down	to	go	to	sleep	only	when	you	are	sleepy.	(2)	Do	not	use	your	bed	for	anything	except	sleep	
and	sexual	activity.	(3)	If	you	find	yourself	unable	to	fall	asleep,	get	up	and	go	to	another	room.	Stay	up	as	long	as	you	wish,	
and	come	back	to	bed	when	you	feel	sleepy.	(4)	If	you	still	cannot	fall	asleep,	repeat	step	3.	Do	this	as	often	as	is	necessary	
throughout	the	night.	(5)	Set	your	alarm	and	get	up	at	the	same	time	every	morning	irrespective	of	how	much	sleep	you	
got	during	the	night.	(6)	Do	not	nap	during	the	daytime
Sleep hygiene 
education
Behavioural and educational strategy:	General	health	instructions	about	internal	and	external	factors	that	might	influence	
sleep	(e.g.,	sport,	light,	temperature,	etc.)
Relaxation Behavioural and cognitive strategy:	A	set	of	methods	that	aim	to	reduce	somatic	or	cognitive	hyperarousal	(e.g.,	progressive	
muscle	relaxation,	autogenic	training,	imagery	training,	meditation)
Cognitive 
reappraisal
Cognitive strategy: Strategies designed to reduce dysfunctional beliefs, attitudes, concerns, and false beliefs about the cause 
of insomnia and about the inability to sleep
Cognitive control/
Worry	time
Cognitive strategy: The patient is instructed to sit comfortably in an armchair and write down a list of worries alongside 
plans	for	the	next	day.	The	rationale	of	this	strategy	is	to	prevent	emotionally	loaded	intrusive	thoughts	during	the	sleep-
onset period, as all worries have been “already” processed before going to bed
Paradoxical	
intention
Cognitive strategy:	Strategy	aimed	at	reducing	the	anticipatory	anxiety	at	the	time	of	falling	asleep.	Patients	are	instructed	
to	remain	still	in	bed	with	their	eyes	closed	and	to	try	to	stay	awake	as	long	as	they	can.	This	reduces	sleep	effort,	which	in	
turn	often	leads	to	falling	asleep	quicker
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be	linked	to	a	current	lack	of	standardization	of	CBT-I,	such	that	the	
treatment, although generally effective, can vary considerably in 
content and duration from clinician to clinician. Moreover, primary 
care practitioners are often poorly informed on sleep disorders, 
which	remain	underdiagnosed	and	sub-optimally	managed	(Grandner	
&	Chakravorty,	2017;	Grandner	&	Malhotra,	2015).	This	is	despite	it	
being well documented that the prevalence of insomnia in primary 
care	patients	is	higher	than	that	in	the	general	population	(Bjorvatn,	
Meland,	Flo,	&	Mildestvedt,	2017;	Grandner	&	Chakravorty,	2017).	
In an Italian observational epidemiological survey, insomnia was re-
ported	by	64%	of	3,284	interviewed	patients	under	738	GPs,	with	
20% reporting both night-time and daytime symptoms and 44% 
complaining	of	night-time	symptoms	only	(Terzano	et	al.,	2004).
There	is	a	high	degree	of	variability	in	both	CBT-I	availability	and	
clinical	administration	across	Europe.	Alongside	a	severe	shortage	of	
European	CBT-I	experts,	 this	variability	calls	 for	greater	efficiency	
and	standardized	certification	of	CBT-I	clinicians	through	examina-
tion	and	 supervised	practice	of	CBT-I's	 core	evidence-based	com-
ponents.	To	address	 this	 situation,	 the	Task	Force	group	collected	
information	on	current	availability	of	CBT-I	education	and	practice	in	
the	12	countries	of	the	founding	members	of	the	Academy	(Austria,	
Estonia,	Finland,	France,	Germany,	 Italy,	Norway,	Poland,	Sweden,	
Switzerland,	the	Netherlands	and	the	UK;	see	Table	3).
It	 should	 be	 stressed	 that	 each	 European	 country	 has	 its	 own	
specific national healthcare system and there is no overarching 
European	healthcare	system	at	an	EU	level.	For	example,	in	the	UK,	
the	National	Health	Service	(NHS)	covers	all	medical	and	health-re-
lated	 issues.	The	NHS	 is	a	 central	health	 service	organized	by	 the	
government through the Department of Health and Social Care; 
everyone	who	lives	in	the	UK	has	equal	access	to	the	NHS	and	its	
benefits	 and	 the	NHS	 is	 financed	 by	 the	 taxpayer.	 In	 France,	 the	
healthcare system also provides universal cover for all citizens irre-
spective of age or socioeconomic status. The costs are covered by 
a combination of central government funding, employment fees and 
healthcare users, who generally pay a low percentage of the cost of 
the	healthcare	(e.g.	medication	and	visits	to	physician)	they	receive.	
The	 Italian	 health	 system	works	 in	 a	 similar	manner	 to	 its	 French	
equivalent.	In	contrast,	the	German	healthcare	system	consists	of	a	
mixture	of	highly	regulated	institutions/processes	organized	through	
the	government	and	a	semi-private	system	 linked	 to	hospitals	and	
private practices. There are several hundred health insurance com-
panies, including so-called “private” health insurance, and premiums 
to health insurance are paid by employers and employees on an 
equal	basis.	In	Sweden,	public	health	care,	which	includes	CBT-I,	is	
financed	through	taxes	and	available	to	all.	The	maximum	fee	paid	by	
the	individual	per	year	for	healthcare	is	approximately	€100/person.	
There is a similar system for medication, which includes approved 
sleeping medications. In addition to the public healthcare system, 
a	 separate	private	 system	exists.	Here	 companies	often	provide	 a	
“healthcare” service to their employees for problems that might 
be	related	to	or	might	affect	work	performance.	These	“corporate	
healthcare	facilities”	quite	often	have	“CBT	therapists”	 (sometimes	
psychologists or psychotherapists, not necessarily licensed, and 
usually	not	 specifically	 trained	 in	 sleep	medicine),	who	will	handle	
sleep	problems	(e.g.,	insomnia	symptoms,	as	these	are	often	related	
to	work	stress	and	might	affect	work	performance).	Some	facilities	
offer	e-versions	of	“CBT-I”	provided	by	private	companies,	although	
these	are	rarely	evaluated	or	quality	controlled.
Exact	 data	 for	 the	 number	 of	 patients	 treated	with	 CBT-I	 per	
year were not available publicly for any of the 12 countries. In many 
European	countries	this	 is	mainly	dependent	on	individual	psycho-
therapists	who	may	offer	CBT-I	and	for	whom	data	are	hard	to	es-
timate.	Where	possible,	 experts'	 estimations	 suggest	 that	CBT-I	 is	
very	seldom	available	for	insomnia	patients	in	Europe.	In	each	coun-
try, only data from specialized clinical centres, either in hospitals 
or	 in	universities,	could	be	tracked.	Via	these	 institutions,	sleep	or	
CBT-I	 experts	 offer	 or	 could	 offer	 training	 for	 health	 profession-
als.	Another	complication	is	that	countries	within	Europe	adhere	to	
differing professional and legal systems regulating the delivery of 
clinical care, including treatment of insomnia. First of all, psycho-
therapists, clinical psychologists, other applied psychologists with 
a licence to practice recognized by the national healthcare system 
and	physicians	(mainly	from	neurology	and	psychiatry)	are	involved	
in insomnia treatment. Sleep specialists in sleep centres may also be 
involved.
It	needs	to	be	emphasized	that	in	many	European	countries	GPs	
have	a	central	role	in	health	care	organization	and	are	seen	as	the	key	
navigators of most healthcare systems. Thus, GPs have a pivotal role 
in treating patients with insomnia. Despite this, available data indi-
cate	that	GPs	rarely	prescribe	or	are	able	to	offer	CBT-I	to	patients	
with	 insomnia	 (e.g.,	Everitt	et	 al.,	2014;	Koffel	 et	 al.,	2018).	 In	 the	
Netherlands,	according	to	national	GP	standards,	GPs	should	offer	
certain	aspects	of	CBT-I.	This	is	often	delivered	by	a	‘practice	assis-
tant’	for	mental	healthcare	at	the	GP's	office	through	internet-based	
therapy	modules.	In	Sweden,	Norway,	Finland	and	the	UK,	insomnia	
is mainly a primary care and/or occupational health issue and man-
aged	 principally	 by	 medication.	 In	 the	 UK,	 however,	 digital	 CBT-I	
(dCBT-I)2	is	currently	being	piloted	(2018/2019)	in	the	southeast	of	
England,	with	access	made	available	to	patients,	free	at	the	point	of	
delivery,	 through	 NHS	 primary	 care	 services.	 In	 Finland,	 a	 public	
sleep	disorder	outpatient	clinic	that	also	focuses	on	complex	insom-
nia	cases	and	the	delivery	of	CBT-I	was	established	in	2016.	
However,	it	is	clear	that	most	patients	with	insomnia	in	Europe	
are never referred to sleep centres. In any case, these centres do 
not typically treat insomnia, and if they do treat it, do not typically 
provide	CBT-I.	Although	insomnia	is	supposed	to	be	handled	in	pri-
mary care, in Sweden it is rarely formally diagnosed and patients 
who complain of sleep problems are generally prescribed sleeping 
medication.	 A	 few	 primary	 care	 centres	 have	 clinicians	 who	 can	
provide	 CBT-I,	 but	 this	 varies	 between	 regions,	 with	 greater	 ac-
cess	 in	 larger	city	 regions	 (similarly	 to	 the	 IAPT	 [Improving	Access	
to	Psychological	Therapies]	services	in	the	UK).	Some	regions	may	
offer	 dCBT-I.	 For	 instance,	 Stockholm	 County	 Public	 Health	 has	
an	 internet	 treatment	 clinic	 (the	 Internet	 Psychiatry	Clinic),	which	
2 Many	authors	use	the	term	Internet	CBT	(ICBT).	In	this	paper,	we	will	use	dCBT-I	to	
refer	to	all	digital	internet-delivered	CBT	for	insomnia.
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provides	CBT-I	with	psychologist	 support	via	 the	 Internet	and	has	
done so since September 2017. The service includes a full psychiatric 
assessment and diagnosis performed by physicians or psychologists. 
The internet treatment is available to all Swedes over the age of 16, 
through	 the	 citizens'	 right	 to	 choose	 their	 health	 centre	 or	 clinic	
for	 outpatient	 care.	Generally	 speaking,	 however,	 it	 is	 a	 challenge	
to	provide	CBT-I	 in	primary	care.	 In	 the	UK,	 there	has	been	some	
recent	project-based	implementation	funding	to	offer	digital	(web/
mobile)	dCBT-I	(Sleepio™)	to	large	populations	(e.g.,	8	million	people	
in	London	for	a	time-limited	period).	The	intention	behind	this	is	to	
find	a	pathway	to	deliver	dCBT-I	to	mainstream	services.	In	France,	
the majority of patients with insomnia are prescribed sleeping med-
ication by their GP, whereas a minority of patients are referred to 
a	sleep	clinic	for	their	 insomnia	complaints.	However,	the	National	
Sleep	 Foundation	 (SFRMS),	 the	 foundation	 Sommeil et Santé and 
the Morphée Network	(Reseau Morphée)	make	efforts	to	address	the	
needs of those with insomnia by providing treatment and special-
ist information online. Reseau Morphée even offers free treatment 
to	severe	insomnia	patients	 in	the	Paris	region	(Londe	et	al.,	2011;	
Storch,	Denesle,	Liyan,	&	Lainey,	2007).	In	France,	group	therapy	is	
also	often	provided	and	online	treatment	is	available	(Hartley	et	al.,	
2016;	Lopez	et	al.,	2017).
Whether	healthcare	professionals	such	as	nurses	or	social	work-
ers	might	 play	 a	 role	 in	 providing	CBT-I,	 as	 suggested	 in	 previous	
publications	(e.g.,	Espie	et	al.,	2008;	Espie,	Inglis,	Tessier,	&	Harvey,	
2001),	remains	to	be	investigated.	In	Finland,	for	example,	CBT-I	is	
effectively delivered by trained nurses in occupational health, show-
ing	long-term	improvements	in	insomnia	symptoms	(Järnefelt	et	al.,	
2014).
Although	 it	 is	clear	 that	differences	 in	the	way	that	healthcare	
is	organized	across	Europe	are	not	a	barrier	to	the	ubiquitous	avail-
ability of pill-based solutions, the structure of health services and 
associated reimbursement mechanisms may play a part in ‘rationing’ 
access	 to	CBT-I.	 Likewise,	 because	CBT-I	 is	 traditionally	 delivered	
face-to-face,	the	shortage	of	training	in	CBT-I	represents	an	intrinsic	
limitation	 to	 the	 scalability	 of	CBT-I	 to	meet	population	need	 and	
demand.	As	shown	in	Table	3,	dCBT-I	is	being	used	to	remedy	this	
problem	 in	some	countries	 (e.g.,	Sweden)	and	 there	are	 large	pilot	
schemes	investigating	feasibility	of	widespread	dCBT-I	provision	un-
derway	(e.g.,	the	UK	and	France).
5  | PRESENT SITUATION OF CBT-I 
TR AINING AND ITS DISSEMINATION IN 
EUROPE
Table	4	summarizes	current	availability	of	CBT-I	education/training	in	
the	12	founder	countries	(Austria,	Estonia,	Finland,	France,	Germany,	
Italy,	Norway,	Poland,	Sweden,	Switzerland,	the	Netherlands	and	the	
UK).	For	some	countries,	such	as	the	UK	and	the	Netherlands,	 for	
reasons of space, no comprehensive course list is provided. Here, 
general information on the types of courses that are available in 
these countries is reported instead.
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Several	CBT-I	courses	are	currently	offered	 in	European	coun-
tries. These are generally given in sleep centres or universities and 
offered to psychologists, specialist physicians and psychotherapists, 
although GPs, nurses and/or other health professionals may also 
be	 included.	Other	than	 in	Norway	 (one	2-day	course),	no	courses	
specifically	 for	 GPs	 are	 offered.	 Trainers	 are	 sleep	 experts,	 both	
psychologists	 and	 medical	 doctors,	 or	 CBT	 experts	 with	 knowl-
edge	of	insomnia.	Most	courses	last	approximately	2	days	and	teach	
core	aspects	of	CBT-I,	 including	CBT-I	strategies	and	the	basics	of	
insomnia and other sleep disorders. The courses often include a 
module on pharmacological treatment. Three courses have a long 
duration,	one	specifically	on	CBT-I,	one	including	different	aspects	
of psychological treatment for sleep disorders and one as a mod-
ule of a Sleep Medicine graduate programme. In Italy, an intensive 
1-year	CBT-I	course	has	been	offered	at	the	“Sapienza”	University	of	
Rome	since	2019.	The	course	includes	12	modules	(covering	basics	
of sleep and sleep disorders, screening and diagnosis of insomnia, 
pharmacological	 treatments,	 sleep	 education,	 CBT-I	 methods,	 re-
laxation,	mindfulness	 techniques,	 techniques	 from	acceptance	and	
commitment therapy, insomnia across the lifespan: basic and clin-
ical	 aspects,	 insomnia	 across	 women's	 lifespan:	 basic	 and	 clinical	
aspects,	and	efficacy	and	limitations	of	CBT-I)	of	8	hr	each,	distrib-
uted	over	12	months.	 In	Austria,	a	three-semester	Sleep	Coaching	
Course	is	offered	at	the	University	of	Vienna.	The	course	includes	
modules	on	sleep	education,	sleep	hygiene,	relaxation,	self-hypno-
sis,	dream	intervention	(including	treatment	of	nightmares),	basics	of	
Gestalt	therapy	(including	awareness	training)	and	pharmacological	
treatment.	Finally,	at	the	University	of	Oxford	in	the	UK,	an	online	
2-year part-time MSc/PgDip in Sleep Medicine was established in 
2016. One of the eight modules is on insomnia, with an emphasis 
on	CBT-I	as	the	preferred	intervention.	As	well	as	the	CBT-I	module	
being	available	online	as	“standalone”	CPD	(continuing	professional	
development),	 the	University	 of	Oxford	 also	 offers	 a	 2-day	 CBT-I	
masterclass	course	delivered	in	person.	All	courses	listed	in	Table	4	
include some form of interactive teaching and some of them provide 
case supervision. The fee is generally paid by the participants. The 
list provided in Table 4 is not, however, comprehensive as it is cur-
rently	difficult	to	gain	a	clear	overview	of	all	CBT-I	trainings	offered	
across	Europe.	Furthermore,	current	provision	 is	not	yet	sufficient	
and varies consistently across countries. Current courses do not yet 
address the different levels of competencies between profession-
als	in	terms	of	both	administering	and	being	able	to	teach	CBT-I.	A	
main	objective	of	 the	CBT-I	Academy	 is	 to	promote	a	coordinated	
European	system	of	CBT-I	training.	which	will	be	formed	of	specialist	
CBT-I	practitioners	and	trainers.	Furthermore,	the	Academy	aims	to	
compile	information	on	current	CBT-I	offered	in	Europe	and	to	pro-
vide a comprehensive list of accredited courses.
6  | THE CBT-I  AC ADEMY
The	Task	Force	group	of	the	European	Sleep	Research	Society	and	the	
European	Insomnia	Network	met	in	May	2018	in	Freiburg	(Germany)	
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and	developed	this	outline	proposal	to	establish	the	European	CBT-I	
Academy	 to	 enable	 a	 Europe-wide	 system	 of	 homogeneous	 CBT-I	
training and training centre accreditation. Deliberations concerned: 
ingredients	of	CBT-I,	how	CBT-I	should	be	administered,	how	to	inte-
grate	CBT-I	training	into	European	healthcare	systems,	preconditions	
and	qualifications	for	health	professionals	to	teach	CBT-I,	the	way	in	
which	CBT-I	should	be	taught	and	to	whom	it	should	be	taught.
6.1 | Ingredients of CBT-I
CBT-I	should	be	defined	as	a	family	of	evidence-based	interventions,	
including behavioural, cognitive and educational interventions. Just 
as	pharmacotherapy	 is	 a	methodology	with	many	drugs,	CBT-I	 is	 a	
system of therapy, not a single therapy. This suggests that the term 
CBT-I	is	used	as	a	convenient	label	but	that	treatment	could	include	
different evidence-based psychological interventions, such as moti-
vational and emotional strategies, which are currently less well de-
fined or standardized. Recently, other psychotherapeutic approaches, 
such as mindfulness and hypnotherapy, centring on powering emo-
tion-regulation	skills,	have	been	empirically	investigated	(Gong	et	al.,	
2016;	Kanen,	Nazir,	Sedky,	&	Pradhan,	2015;	Lam	et	al.,	2015)	and	
acceptance and commitment therapy has been proposed as a pos-
sible	 intervention	 for	 non-responders	 to	 CBT-I	 (Hertenstein	 et	 al.,	
2014).	Together	with	the	main	strategies	listed	in	Table	2,	knowledge	
on sleeping medication tapering or withdrawal should be considered 
a	component	of	CBT-I.	The	 insomnia	 research	 literature	provides	a	
strong evidence base, with proof of efficacy and clinical effective-
ness,	both	for	multicomponent	CBT-I	and	also	for	single	components,	
such	as	sleep	 restriction,	 stimulus	control	and	 relaxation	 therapies,	
and	to	a	lesser	extent	cognitive	therapies.	The	decision	as	to	whether	
to	 apply	 CBT-I	 as	 a	 ‘package’	 intervention	 or	 as	 individual	 compo-
nents	should	be	at	the	discretion	of	expert	clinicians	or	defined	in	a	
stepped-care	model,	as	discussed	in	the	next	paragraph.
6.2 | How CBT-I should be administered
6.2.1 | A stepped-care approach to insomnia
In	order	to	increase	the	likelihood	of	sufficient	evidence-based	thera-
peutic	provision	for	insomnia	across	Europe,	we	suggest	the	adoption	
of	a	stepped-care	approach	inspired	by	the	model	proposed	by	Espie	
(2009)	and	Espie,	Hames,	and	McKinstry	(2013).	This	model	promotes	
the idea that the greatest numbers of patients could be managed 
through	 readily	 accessible	 self-help	 therapies,	 including	 dCBT-I	 via	
the	internet	and	mobile	devices,	as	well	as	books	and	audio	resources.	
There	 is	 now	 a	 substantial	 evidence	 base	 for	 dCBT-I	 and	 such	 ap-
proaches	have	been	incorporated	into	clinical	guidelines	(e.g.,	Wilson	
et	al.,	2019).	Dependent	upon	treatment	response,	clinical	complexity	
and/or treatment preference, patients may be ‘stepped-up’ to a more 
time	 and	 resource-intensive	 level	 of	 CBT-I;	 for	 example,	 including	
manualized treatment delivered by trained therapists. Three further 
steps	are	suggested	in	the	model,	gradually	increasing	the	expertise	
of the therapist and adaptation of the intervention to the needs of the 
patient.	These	three	steps	range	from	“individual	or	small	group	CBT	
delivered	by	a	graduate	psychologist”	to	“individually	tailored	CBT	de-
livered	by	a	clinical	psychologist”	to	“expert	CBT	delivered	by	behav-
ioural	sleep	medicine	expert”.	The	purpose	of	the	stepped-care	model	
is twofold: first, to help individual patients find the best approach for 
them,	and	second,	to	develop	a	high-quality	service	at	a	population	
level that is both effective and economically viable.
Here	we	propose	a	simplification	of	the	model	proposed	by	Espie	
(2009)	and	Espie	et	al.	(2013),	which	could	be	adapted	for	use	within	
a	 given	national	 health	 system.	A	 first	 level	 includes	prescriptions	
from GPs for behavioural treatment of insomnia or evidence-based 
dCBT-I	 developed	 by	 an	 expert	 therapist	 and	 promoted	 by	 well-
known	health	systems.	It	could	be	that	the	GP	or	other	professional	
recommends, or in some way ‘prescribes’, this solution; or it could 
be	that	the	responsible	health	authority	(such	as	the	NHS	in	the	UK)	
promotes ready access even more directly. The clear intention, how-
ever,	would	be	to	develop	services	in	such	a	way	that	CBT-I	becomes	
available	at	a	scale	equivalent	to	medication.	The	important	point	is	
that	patients	and	their	GPs	would	have	immediate	access	to	CBT-I.	
Of	course,	this	is	an	ideal	model,	would	take	time	to	develop	and	will	
initially be based, where a clinician is involved, on appraisal of the pa-
tient's	needs,	preferences	about	formats	of	engagement,	as	well	as	
what is on offer locally. Ideally, such an insomnia care pathway would 
also	 involve	patients	somehow	being	reviewed	after	4–6	weeks	to	
ascertain their degree of treatment response.
Based	on	patients'	response	to	this	initial	step	(GPs’	prescriptions	
or	dCBT-I),	complexity	or	patients'	preference	and	what	is	available	
locally,	two	higher	levels	of	treatment	are	then	suggested:	(a)	man-
ualized	CBT-I	 delivered	 by	 a	 trained	 therapist,	 either	 face	 to	 face	
or	via	the	 internet	 in	small	groups,	or	 (b)	 individually	tailored	ther-
apy	delivered	by	a	CBT-I	expert	face	to	face	individually	or	through	
group	therapy.	The	use	of	dCBT-I	programmes	could	also	be	useful	in	
these	stages	because	one	goal	of	CBT	is	to	enable	patients	to	imple-
ment effective therapy components at home in between traditional 
treatment sessions. The stepped-care model, therefore, reflects a 
pyramid of therapeutics gradually increasing the level of therapist/ 
clinician	 expertise	 and	 time	 commitment.	 Stepped	 care	 therefore	
conserves	these	most	expensive	of	human	resources	for	those	situ-
ations	where	they	are	most	required,	whilst	optimizing	the	volume	
of patients who can be successfully and effectively treated. It is not 
necessary that each patient tries all steps, but rather the allocation 
to the best-fitting therapy would depend on insomnia severity or 
complexity,	therapist/clinician	judgement	and/or	patient	preference.	
The model is summarized in Figure 1.
6.3 | How to integrate CBT-I training into the 
healthcare systems in Europe?
It is clear that, given the heterogeneous situation of healthcare 
in	 Europe,	 no	 unified	 training	 model	 can	 be	 proposed.	 We	 will,	
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instead, suggest an ‘ideal’ generic model, which has the potential to 
be	adapted	to	 the	healthcare	system	of	each	respective	European	
country.
Here we provide a brief overview of what has been published 
to	 date	 about	 how	 to	 integrate	 CBT-I	 into	 general	 healthcare.	 In	
Appendix	 1,	 a	 list	 of	 relevant	 publications	 directed	 at	 the	 general	
population	in	different	European	languages	is	provided.
Perlis	and	Smith	(2008	speculated	upon	how	to	make	CBT-I	ser-
vices	more	widely	available,	with	a	focus	on	the	USA.	Their	approach	
led to the establishment of a behavioural sleep medicine specialty 
within the broader sleep medicine field. The behavioural sleep medi-
cine	provider	is	able	to	offer	CBT-I,	alongside	other	behavioural	sleep	
treatments	and	expertise,	and	is	affiliated	to	AASM-accredited	sleep	
centres	(Perlis	&	Smith,	2008).	Curricula	for	CBT-I	are	developed	and	
endorsed	by	the	AASM	and	the	BSM	Committee.	The	authors	rec-
ommended the development of intensive training opportunities for 
CBT-I.	When	one	considers	the	ubiquitous	availability	of	second-line	
treatments	 such	 as	 hypnotics	 (numbering	 billions	 of	 prescriptions	
worldwide),	it	is	clear	that	CBT-I	has	a	very	long	way	to	go	to	offer	
patients the choice of an alternative treatment path.
It	 is	our	suggestion	that,	 in	Europe,	the	CBT-I	Academy	should	
not	be	exclusively	tied	professionally	to	the	field	of	sleep	medicine.	
Rather, and necessarily, there should be strong connections to the 
field of cognitive and behavioural psychotherapy/psychiatry. Thus, 
expert	providers	of	CBT-I	would	by	definition	already	be	health	pro-
fessionals with a recognized license to provide clinical psychology/
psychotherapy/mental healthcare, but who have further to that 
obtained	 qualification	 and	 the	 associated	 supervised	 education	
and practice in sleep medicine and sleep clinical psychology. That 
is,	CBT-I	 clinicians	 should	be	also	 fully	 licensed	and	 insured	 for	all	
of	their	working	healthcare	practice	and	should	practice	within	the	
boundaries of their professional training. The important caveat here 
is	that	a	CBT-I	practitioner	must	already	possess	a	license	to	practice	
clinically,	and	that	simply	undertaking	a	CBT-I	course	does	not	in	it-
self confer a license to see patients.
There is a parallel here with medical management in that a li-
censed	physician	is	intrinsically	qualified	to	prescribe	medication,	in-
cluding	that	not	yet	developed	or	distributed,	but	is	likely	to	require	
further orientation to and training in a particular therapy or thera-
peutic approach. In the same way, a licensed clinical or practitioner 
psychologist,	psychotherapist	or	psychiatrist	 is	already	qualified	to	
see	patients	and	to	take	clinical	responsibility	based	on	their	national	
laws	and	professional	regulations,	and	is	best	placed	to	extend	his	or	
her	skills	into	the	CBT/insomnia	area.
6.4 | Preconditions for health professionals to teach 
CBT-I
One	aim	of	the	CBT-I	Academy	 is	to	establish	a	qualification	pro-
cedure;	that	is,	professionals	intending	to	practise	CBT-I	should	be	
adequately	trained.	This	academy	approach	would	be	expected	to	
facilitate	an	 increase	 in	the	number	of	health	experts	 in	CBT-I,	 to	
improve focus on effective clinical practice in insomnia care and to 
reduce treatment variability across clinicians. In order to inaugurate 
the	academy,	at	the	end	of	2017	interested	insomnia	expert	clini-
cians	and	members	of	the	European	Insomnia	Network	(EIN)	were	
invited	 by	 e-mail	 to	 take	 part	 in	 the	 initiative.	Attendees	worked	
F I G U R E  1  An	evidence-based	
stepped-care	model	for	CBT-I.
Individual tailored CBT-I 
administered by 
psychotherapists 
qualified as CBT-I 
experts. At this step, 
the therapist should be 
highly familiar with all 
CBT-I strategies, as 
well as other innovative 
interventions.  
Manualized CBT-I: delivered using internet therapy, face-
to-face group therapy, individual therapy administered by 
health professionals qualified as CBT-I experts. Ideally, 
different programmes/protocols should exist in all European 
languages for all possible target populations. These should 
include different CBT-I components and eventually 
motivational/emotional additional strategies.
GPs: basic information on sleep, insomnia and CBT-I core strategies (sleep restriction 
and stimulus control) for all possible populations. 
Digital CBT (dCBT) or Internet CBT (ICBT) for insomnia: developed by an expert 
therapist and supported through an established national health system. This should 
include different CBT-I components.  
+ Self-administered CBT-I delivered by booklet, CD/DVD* (made by health 
professionals qualified as CBT-I experts) recommended by GPs or dCBT 
programmes.  
Assessment/ 
Allocation 
Review/discharge/ 
Refer on 
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together	 to	 prepare	 the	 present	 manuscript	 (the	 authors	 of	 this	
paper).	At	the	first	Academy	meeting,	which	took	place	in	Freiburg,	
Germany, on May 4th, 2018, the authors of the present paper and 
founding	members	of	the	Academy	were	declared	first-generation	
trainers	(“grandmothers	and	grandfathers”)	qualified	as	CBT-I	train-
ers and practitioners. Figure 2 provides a list of the founding mem-
bers	 of	 the	 Academy.	 A	 Steering	 Committee	 was	 elected	 during	
the	inaugural	Freiburg	meeting,	comprised	of	two	chairs	(D.R.	and	
C.A.E.)	and	five	members	(E.A.,	C.B.,	S.J.,	A.S.	and	B.H.).	The	CBT-I	
Academy	Steering	Committee	will	have	the	task	of	reviewing	and	
approving	course	proposals,	creating	a	European	register	of	CBT-I	
practitioners	 (by	merging	data	 from	national	 registers;	see	below)	
and	coordinating	new	initiatives	to	promote	CBT-I	education	across	
Europe.
We	assume	that	until	this	point	no	European	country	has	a	gov-
erning body controlling whether or not somebody is competent to 
practice	CBT-I.	On	 the	other	hand,	most	European	countries	have	
governing bodies controlling who is permitted to practise clinical 
psychology or psychotherapy, or to call themselves a psychother-
apist.	 In	 establishing	 the	 CBT-I	 Academy	 our	 starting	 assumption	
is that eligible individuals have a legitimate license to practice in a 
clinical	 context.	That	 is,	CBT-I	 skills	 can	only	be	an	extension	of	a	
person's	practising	certificate.	It	is	that	certification	(e.g.,	as	a	phy-
sician, clinical psychologist, health or practitioner psychologist, or 
psychotherapist)	that	provides	the	governance	structure	enabling	a	
person to see patients, and thus to be regulated as a professional in 
their	country	of	practice.	The	first-generation	European	trainers	all	
meet	 these	criteria,	 in	addition	 to	which	 they	have	 recognized	ex-
pertise	in	CBT-I,	being	members	of	the	European	Insomnia	Network	
(EIN).	Moreover,	the	foundation	of	the	Academy	could	benefit	from	
the	collaboration	with	world-leading	experts	in	CBT-I	from	the	USA.	
The	 founding	 members	 have	 been	 selected	 as	 European	 repre-
sentatives; they also represent and are in close contact with other 
well-established	 CBT-I	 professionals	 in	 their	 respective	 countries.	
Further	 first-generation	CBT-I	 expert	 clinicians	 and	 trainers	 could	
be	added	to	the	Academy	if	they	are	established	CBT-I	clinical	pro-
fessionals	with	widely	recognized	expertise	in	CBT-I	clinical	and	re-
search aspects and are sponsored by the founding members.
Second-generation	 CBT-I	 expert	 clinicians	 and	 trainers	will	 be	
health	professionals	who	(a)	have	a	licence	to	practice	clinically	and	
(b)	have	attended	an	accredited	CBT-I	course.	Thus,	they	will	be	able	
to	practise	CBT-I	as	a	form	of	psychological	treatment.
Ideally,	three	levels	of	expertise	should	be	considered.
1. Expert level:	 This	 level	 of	 expertise	would	 allow	 licensed	health	
professionals	 to	 be	 expert	 CBT-I	 practitioners,	 who	 are	 able	
to	 conduct	 individually	 tailored	 CBT-I.	 This	 level	 of	 expertise	
is suited to clinical and healthcare psychologists, psychothera-
pists,	 psychiatrists	 and	 sleep	 experts	 whose	 CBT-I	 expertise	 is	
core	to	their	professional	clinician	 level	knowledge.	They	would	
be	 expected	 to	 have	 attended	 a	 high-quality,	 certified	 course,	
endorsed	 by	 the	 Academy,	 and	 have	 followed	 at	 least	 three	
cases	 over	 the	 course	 of	 3–6	 months	 under	 the	 guidance	 of	
a	 CBT-I	 qualified	 expert.	 CBT-I	 practitioners	 with	 certificated	
knowledge	in	sleep	medicine	and	sleep	clinical	psychology	could	
operate	 also	 as	 CBT-I	 trainers	 and	 supervisors.
2. Advanced level:	 This	 advanced	 level	 of	 expertise	 would	 allow	
health professionals to be trained therapists who could conduct 
manualized	 CBT-I	 delivered	 face	 to	 face	 or	 digitally,	 under	 the	
supervision	of	an	expert-level	CBT-I	supervisor.	This	level	of	ex-
pertise	would	be	suited	to	clinical	and	health	psychology	master's	
graduates and psychiatrists in training and, in some countries, 
nurses	or	social	workers.	To	be	entitled	to	an	advanced	 level	of	
expertise,	 practitioners	would	 be	 expected	 to	 have	 attended	 a	
certified	course,	endorsed	by	the	Academy,	including	interactive	
and supervising activities.
F I G U R E  2   List of founding members 
of	the	European	CBT-I	Academy.
THE EUROPEAN CBT-I ACADEMY:
AN INITIATIVE OF THE EUROPEAN INSOMNIA NETWORK
STEERING COMMITTEE
Chairs: Dieter Riemann (Germany), Colin A. Espie (UK). 
Members: Ellemarije Altena (France), Chiara Baglioni (Italy, Germany), Susanna Jernelöv (Sweden), 
Angelika Schlarb (Germany), Brigie Holzinger (Austria). 
First (founding) members of the CBT-I Academy: Ellemarije Altena (France), Chiara Baglioni (Italy, 
Germany), Bjørn Bjorvatn (Norway), Kersn Blom (Sweden), Kristoffer Bothelius (Sweden), Alessandra 
Devoto (Italy), Colin A. Espie (UK), Lukas Frase (Germany), Dimitri Gavriloff (UK), Tuuliki Hion (Estonia), 
Andrea Hoflehner (Austria), Brigie Holzinger (Austria), Heli Järnefelt (Finland), Susanna Jernelöv
(Sweden), Anna F. Johann (Germany), Caterina Lombardo (Italy), Christoph Nissen (Switzerland), Laura 
Palagini (Italy),  Geert Peeters (The Netherlands), Dieter Riemann (Germany), Angelika Schlarb 
(Germany), Kai Spiegelhalder (Germany), Adam Wichniak (Poland), Birgit Högl (Austria).  
Non-European Members: Michael L. Perlis (USA), Donn Posner (USA).
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3.	 Foundation level:	 This	 level	 of	 expertise	 is	 specifically	 suited	 to	
GPs	 and	 should	 reflect	more	 basic	 knowledge	 of	 CBT-I	 behav-
ioural strategies and sleep medicine obtained through attendance 
at	a	CBT-I	Academy	certified	course.
The	 Academy	 will	 identify	 these	 three	 levels	 of	 expertise	 by	
classifying endorsed courses following this three-level categoriza-
tion.	As	a	consequence,	 trained	CBT-I	practitioners,	depending	on	
the	course(s)	attended,	will	then	be	recognized	by	the	Academy	as	
CBT-I	practitioners	at	 the	expert,	 advanced	or	 foundation	 level	of	
expertise.	After	publication	of	 this	paper,	 the	Steering	Committee	
will create a register and an associated website containing all the rel-
evant	information	on	the	processes	and	initiatives	of	the	Academy.	
In this way, the registered list of founding, first-generation and sec-
ond-generation	 members,	 their	 qualifications	 and	 their	 levels	 of	
CBT-I	expertise	will	be	in	the	public	domain.
6.5 | The way in which CBT-I should be taught
Table	 5	 summarizes	 the	 CBT-I	 course	 criteria	 identified	 by	 the	
Academy.	Courses	for	aspiring	CBT-I	practitioners	of	any	level	should	
be of a minimum of 2 days in duration and may be offered to peo-
ple	with	pre-existing	qualifications	in	different	healthcare	areas	with	
a	recognized	licence	to	see	patients	in	mental	healthcare	contexts.	
Courses should include teaching on sleep itself, on insomnia disorder 
and	 its	assessment,	as	well	as	on	core	CBT-I	components	 (such	as	
behavioural	 and	 cognitive	 intervention)	 and	additional	CBT-I	 com-
ponents	 (such	 as	 emotional	 and	 motivational	 strategies).	 Courses	
directed	at	a	foundation	level	of	expertise	may	focus	specifically	on	
CBT-I	behavioural	components.	Courses	should	include	conceptual	
elements covering sleep mechanisms and pathophysiology; theo-
retical underpinnings of insomnia development and maintenance; 
formulation	of	CBT	as	an	 intervention.	The	stepped-care	model	of	
insomnia service delivery may be also taught. Courses should cover 
basic	principles	of	CBT	therapy.	A	module	on	sleep	medication	and	
tapering off/withdrawing medication should be included. Depending 
on national laws, some health professionals may be prohibited from 
discussing any change in medication status with patients as they do 
not	 have	 the	 necessary	 professional	 competences.	 Nevertheless,	
any health professional dealing with patients with insomnia at a 
clinical level should be aware of sleep medication mechanisms and 
effects	during	intake	and	withdrawal.	Courses	should	be	organized	
to	be	interactive	(e.g.,	role	playing,	work	in	small	groups	and	difficult	
situations)	and	case	supervision	should	be	offered.	It	is	possible	that	
some	 elements	 of	 the	 CBT-I	 programme	 could	 involve	 interactive	
training and be offered online.
For	the	expert	 level,	courses	should	comprise	extensive	teach-
ing	of	the	individual	tailoring	of	treatment,	advanced	knowledge	on	
sleep	medicine,	insomnia	and	CBT	principles,	and	clinical	experience	
(e.g.,	at	least	three	case	studies),	and	either	have	a	long-term	dura-
tion or include a follow-up/refresher course to discusses cases.
Trainers	should	all	be	expert-level	CBT-I	professionals. T
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These criteria are not intended to be overly prescriptive, neither 
are they completely comprehensive. However, we have attempted 
to	 set	 expectations	 and	minimum	 standards	 for	 what	 may	 be	 re-
garded as necessary and feasible.
6.6 | How courses may become endorsed
It	 is	proposed	that	the	qualification	and	training	standards	set	by	
the	Academy	will	first	be	approved	by	the	ESRS	and	its	special	in-
terest	 group	 in	 insomnia,	 the	 European	 Insomnia	Network	 (EIN).	
Once	 this	 is	 the	case,	 the	Academy	will	be	 in	a	position	 to	 invite	
submissions with a view to reviewing them against training criteria 
and then to provide approval. It is hoped that this process will en-
courage organizations, institutions and local societies to develop 
high-quality	 curricula	 and	 that	 the	 ESRS	 imprimatur	 of	 endorse-
ment will encourage health professionals to apply for and to com-
plete	CBT	training.
Appendix	2	comprises	a	form	that	could	be	used	for	submitting	
course	proposals.	The	form	will	be	uploaded	and	updated	on	the	ESRS	
website.	To	support	the	process,	it	is	suggested	that	each	European	
country	 designates	 a	 central	 National	 CBT-I	 Training	 Centre	 (i.e.,	
centre	 of	 excellence	 for	 CBT-I).	 For	 countries	where	 there	 are	 al-
ready	 several	 established	 centres,	 a	 collaborative	 network	 could	
be	formed	to	support	education	and	dissemination	of	CBT-I.	These	
centres	should	have	on	board	a	medical	specialist	(general	medicine,	
psychiatry,	neurology	or	sleep	medicine)	or	a	clinical	psychologist/
psychotherapist who is accredited to practice medicine/psychiatry/
psychotherapy in her/his given country. Furthermore, these persons 
should	have	accredited	expertise	to	practise	and	supervise	psycho-
therapy	 and	 CBT-I.	 Each	 country	 should	 also	 establish	 a	 national	
register	of	CBT-I	practitioners.	This	could	be	achieved	in	collabora-
tion with the national sleep society or national clinical psychology 
or	cognitive	behavioural	therapy	associations.	In	Appendix	3	a	form	
for national registers is provided. The national registers also will be 
uploaded	and	updated	on	the	ESRS	website.
7  | CONCLUSIONS
The	 European	 guidelines	 for	 insomnia	 (Riemann,	 Baglioni,	 et	 al.,	
2017)	 highlighted	 that	 “cognitive	 behavioural	 therapy	 for	 insom-
nia, although being the first-line treatment for insomnia, is not 
easily available. It is assumed that only a minority of patients with 
chronic	 insomnia	will	 receive	 this	 treatment	 in	Europe.	Thus,	 the	
widespread	implementation	of	CBT-I	will	be	a	major	challenge	for	
the	future.”	In	response	to	this	statement,	European	CBT-I	experts	
from	 12	 different	 countries	 have	 instituted	 the	 CBT-I	 Academy,	
with	 the	 aim	 of	 establishing	 and	 promoting	 Europe-wide	 stand-
ards	 for	CBT-I	 training	 and	 training	 centre	 accreditation.	 The	 in-
tention	 is	 to	substantially	 improve	 the	availability	of	high-quality	
CBT-I	 in	Europe	within	 the	next	10	years.	 In	 this	paper,	we	have	
highlighted	the	very	limited	availability	of	CBT-I	across	Europe	and	
summarized	 the	 current	 availability	 of	 training	 in	 CBT-I.	 Despite	
differences between countries, the general conclusion is that ac-
cess	to	CBT-I	for	patients	and	training	in	CBT-I	for	health	profes-
sionals	 are	 poor	 and	 require	 standardization.	 Thus,	 as	 founders	
of	 the	 CBT-I	 Academy,	 we	 have	 proposed	 minimal	 criteria	 that	
should	be	met	in	each	country	to	provide	adequate	CBT-I	training	
at	 differing	 expertise	 levels	 for	 health	 professionals,	 alongside	 a	
stepped-care	 approach	 to	 service	 delivery.	 This	 is	 also	 expected	
to impact clinical research standards. It is desirable that clinical 
trials	involving	CBT-I	will	involve	CBT-I	trained	practitioners.	This	
would	 impact	very	positively	on	the	quality	and	comparability	of	
CBT-I	clinical	studies	across	Europe.	A	closer	relationship	between	
clinical	practice	and	research	contexts	would	also	be	expected	to	
add	to	the	current	evidence	base	of	CBT-I,	particularly	with	regard	
to the diverse groups of patients seen clinically, including chil-
dren and young people, pregnant women, women at postpartum, 
women	going	 through	 the	menopause,	 shift	workers,	 those	with	
disabilities and retirees.
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CBT- I  COURSE PROPOSAL FORM ( TO BE SUBMIT TED TO CBT- I  AC ADEMY S TEERING COMMIT TEE)
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Provide	a	full	list	of	the	course's	teachers,	their	qualification	and	what	topic	they	teach.
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Person(s) in charge
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Qualification of the 
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CBT- I  NATIONAL REG IS TER ( TO BE SUBMIT TED TO CBT- I  AC ADEMY S TEERING COMMIT TEE)
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